Abstract 1091P
Background
In BRAF mutant resected melanoma, both targeted therapy and immunotherapy have shown durable clinical benefit as 1st line (1L) adjuvant therapy. However, there are no clinical studies evaluating 2nd line (2L) adjuvant targeted therapy in patients with locoregional relapse and complete surgical resection following initial adjuvant immunotherapy.
Methods
This was a retrospective, multicenter chart review study of BRAF V600-mutated stage III/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant checkpoint inhibitor therapy, then relapsed locoregionally or distantly, were again resected to NED, and then treated with dabrafenib/trametinib (dab/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS-2) after initiation of dab/tram therapy. Secondary endpoints included overall survival (OS) and distant metastasis-free survival (DMFS). Analyses were descriptive with event time endpoints (RFS-2, OS, DMFS) estimated using the Kaplan-Meier method.
Results
A total of 37 patients were included (median age 51 years, 62% male, 89% stage III, median follow-up of 19 months from dab/tram initiation). Median time to dab/tram initiation after repeat resection to NED was 0.9 months (range: 0.2 – 2.8 months). A majority (73%) had discontinued dab/tram by last follow-up, with median therapy duration of 10.1 months (range: 1 day – 22.7 months). Median (95% confidence interval [CI]) RFS-2 was 18.9 (14.9 – 28.1) months, with 91% and 81% remaining relapse-free at 12 and 18 months, respectively; most patients also remained distant metastasis-free at 6 months (97%) and 12 months (85%). Only 2 patients were deceased at last follow-up, with nearly all patients (97%) still alive at 18 months; median OS was not reached.
Conclusions
More than 80% of patients remained relapse- and metastasis-free for at least 12 months after initiation of dab/tram. Longer follow-up and a larger patient cohort is needed in future studies to confirm efficacy of 2L adjuvant dab/tram in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis.
Funding
Novartis.
Disclosure
J.S. Weber: Financial Interests, Personal, Advisory Board, Ad Boards: BMS; Financial Interests, Personal, Advisory Board: Merck, GSK, Incyte, Genentech, Pfizer, Biond, OncoC4, AstraZeneca, Regeneron, ImCheck, Novartis; Financial Interests, Personal, Stocks/Shares: Biond, Evaxion, Instil Bio, OncoC4; Financial Interests, Personal, Royalties: Moffitt Cancer Center; Financial Interests, Institutional, Local PI: BMS, Regeneron; Financial Interests, Institutional, Coordinating PI: Merck, Novartis; Non-Financial Interests, Principal Investigator: Moderna, BMS; Non-Financial Interests, Member: ASCO. S.N. Markovic: Financial Interests, Institutional, Royalties: Sorrento; Financial Interests, Institutional, Research Grant: Sorrento; Non-Financial Interests, Institutional, Research Grant: BMS; Non-Financial Interests, Institutional, Local PI: BMS. A.K.S. Salama: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Iovance, Regeneron, Replimune, Novartis, Pfizer; Financial Interests, Institutional, Invited Speaker: Bristol Myers Squibb, Ascentage, IDEAYA, Immunocore, Merck, Olatec, Regeneron, Replimune, Seagen. I. Mehmi: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca. R.J. Sullivan: Financial Interests, Personal, Advisory Board: Merck, Novartis, Bristol Myers Squibb, Eisai, Iovance, OncoSec, Pfizer, Replimune, Marengo; Financial Interests, Personal, Royalties: Up-To-Date; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Invited Speaker: GSK, Pfizer, Sanofi, Moderna, Roche-Genentech, BioMed Valley Discoveries, Astex, Compugen, Beigene, Novartis, Rubius, Alkermes, Simcha Therapeutics, OnKure, Marengo, Synthekine. Y.G. Najjar: Financial Interests, Personal, Advisory Board: Immunocore, InterVenn Bio, Merck, BMS, Pfizer, Novartis; Financial Interests, Personal, Invited Speaker: Immunocore, Pfizer; Non-Financial Interests, Institutional, Funding: Merck, Pfizer, BMS, Replimune. A.C.J. van Akkooi: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Sirius Medical, 4SC, Provectus; Financial Interests, Institutional, Research Grant, NIVEC study: Amgen; Financial Interests, Institutional, Research Grant: Merck-Pfizer. A.M. Menzies: Financial Interests, Personal, Advisory Board, advisory board: BMS, MSD, Novartis, Roche, Pierre Fabre, QBiotics. G.V. Long: Other, Personal, Advisory Role: Agenus Inc., Amgen Inc., Array Biopharma, Boehringer Ingelheim, BMS, Evaxion Biotech, Hexal AG, Highlight Therapeutics, Innovent Biologics, MSD, Novartis Pharmaceuticals, OncoSec, PHMR, Pierre Fabre, Provectus, QBiotics, Regeneron. J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Achilles Therapeutics, Ipsen, Merck Sharp & Dohme, Merck Serono, Pfizer, Molecular Partners, Novartis, Roche, Sanofi, Third Rock Venture, Iovance Biotherapeutics; Financial Interests, Institutional, Advisory Board, SAB member: BioNTech, Immunocore, Gadeta, Instil Bio, PokeAcel, T-Knife; Financial Interests, Personal, Advisory Board, SAB member: Neogene Therapeutics, Scenic; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, BioNTech US, Merck Sharp & Dohme, Amgen, Novartis, Asher Bio; Non-Financial Interests, Member: ASCO, AACR, SITC; Other, Other, Editor-in-Chief IOTECH: ESMO; Other, Other, Editorial Board ESMO Open: ESMO; Other, Other, Editorial Board: Kidney Cancer. K. Davis: Financial Interests, Institutional, Funding: Novartis, AstraZeneca, Eisai, Gilead, Pfizer, Merck, Bristol Myers Squibb. S. Karanth: Financial Interests, Institutional, Funding, Full-time employee of RTI Health Solutions, an independent non-profit research organization, which was retained by Novartis to conduct the research that is being submitted to ESMO. Compensation is unconnected to the studies on which I work: Novartis; Financial Interests, Institutional, Funding, Full-time employee of RTI Health Solutions, an independent non-profit research organization, which was retained by Pfizer to conduct the research that is being submitted to ESMO. Compensation is unconnected to the studies on which I work: Pfizer. R. Shah: Financial Interests, Personal, Full or part-time Employment, Medical Director at Novartis: Novartis. L. Connolly: Financial Interests, Personal, Stocks/Shares: Novartis. D. Norton: Financial Interests, Institutional, Full or part-time Employment, work as head of Medical team for GI in the US: Novartis; Financial Interests, Institutional, Stocks/Shares, work as head of Medical team for GI in the US: Novartis; Financial Interests, Institutional, Funding, work as head of Medical team for GI in the US: Novartis; Non-Financial Interests, Leadership Role, work as head of Medical team for GI in the US: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12
942P - Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1092P - Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Presenter: Manja Bloem
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12